131 related articles for article (PubMed ID: 8409409)
41. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.
Li Q; Furman SA; Bradford CR; Chang AE
Clin Cancer Res; 1999 Feb; 5(2):461-9. PubMed ID: 10037198
[TBL] [Abstract][Full Text] [Related]
42. Antigen receptor-mediated transmembrane signaling in Wiskott-Aldrich syndrome.
Henriquez NV; Rijkers GT; Zegers BJ
J Immunol; 1994 Jul; 153(1):395-9. PubMed ID: 7515927
[TBL] [Abstract][Full Text] [Related]
43. Polymorphisms of the T cell receptor CD3delta and CD3epsilon chains affect anti-CD3 antibody binding and T cell activation.
Boding L; Nielsen MW; Bonefeld CM; von Essen MR; Nielsen BL; Lauritsen JP; Hansen AK; Nielsen MM; Kongsbak M; Rubin M; Vennegaard MT; Odum N; Geisler C
Mol Immunol; 2010 Sep; 47(15):2450-7. PubMed ID: 20638133
[TBL] [Abstract][Full Text] [Related]
44. Glycosyl phosphatidylinositol membrane anchor is not required for T cell activation through CD73.
Resta R; Hooker SW; Laurent AB; Shuck JK; Misumi Y; Ikehara Y; Koretzky GA; Thompson LF
J Immunol; 1994 Aug; 153(3):1046-53. PubMed ID: 8027539
[TBL] [Abstract][Full Text] [Related]
45. T lymphocytes from alcoholic cirrhotic patients show normal interleukin-2 production but a defective proliferative response to polyclonal mitogens.
Girón-González JA; Alvarez-Mon M; Menéndez-Caro JL; Manzano L; Abreu L; Yebra M; Durántez-Martínez A
Am J Gastroenterol; 1994 May; 89(5):767-73. PubMed ID: 8172154
[TBL] [Abstract][Full Text] [Related]
46. Identification of heavy chain residues in a humanized anti-CD3 antibody important for efficient antigen binding and T cell activation.
Zhu Z; Carter P
J Immunol; 1995 Aug; 155(4):1903-10. PubMed ID: 7636241
[TBL] [Abstract][Full Text] [Related]
47. An anti-CD2 monoclonal antibody that both inhibits and stimulates T cell activation recognizes a subregion of CD2 distinct from known ligand-binding sites.
Kozarsky KF; Tsai C; Bott CM; Allada G; Li LL; Fox DA
Cell Immunol; 1993 Sep; 150(2):235-46. PubMed ID: 8103706
[TBL] [Abstract][Full Text] [Related]
48. Defective actin reorganization and polymerization of Wiskott-Aldrich T cells in response to CD3-mediated stimulation.
Gallego MD; Santamaría M; Peña J; Molina IJ
Blood; 1997 Oct; 90(8):3089-97. PubMed ID: 9376590
[TBL] [Abstract][Full Text] [Related]
49. Disorders of regulatory T cell function in patients with the Wiskott-Aldrich syndrome.
Zabay JM; Fontán G; Campos A; García-Rodriguez MC; Pascual-Salcedo D; Bootello A; de la Concha EG
Clin Exp Immunol; 1984 Apr; 56(1):23-8. PubMed ID: 6609033
[TBL] [Abstract][Full Text] [Related]
50. Relevance of anti-T monoclonal antibodies in the study of children with primary immunodeficiencies.
Tovo PA; Gabiano C; Roncarolo MG; Delpiano AM; Saitta M; Giubellino MC; Foa R
Boll Ist Sieroter Milan; 1985; 64(2):135-41. PubMed ID: 2992541
[TBL] [Abstract][Full Text] [Related]
51. Relationship between IL 2 synthesis and the proliferative response to PHA in different primary immunodeficiencies.
López-Botet M; Fontán G; Garcia Rodriguez MC; de Landázuri MO
J Immunol; 1982 Feb; 128(2):679-83. PubMed ID: 6976384
[No Abstract] [Full Text] [Related]
52. Functional thrombin receptors on human T lymphoblastoid cells.
Tordai A; Fenton JW; Andersen T; Gelfand EW
J Immunol; 1993 Jun; 150(11):4876-86. PubMed ID: 8388423
[TBL] [Abstract][Full Text] [Related]
53. Lymphocyte dysfunction in cartilage-hair hypoplasia: evidence for an intrinsic defect in cellular proliferation.
Pierce GF; Polmar SH
J Immunol; 1982 Aug; 129(2):570-5. PubMed ID: 6806374
[TBL] [Abstract][Full Text] [Related]
54. Impairment of lymphocyte function in patients with myelodysplastic syndrome and its correction by addition of Ca2+ ionophore and phorbol myristate acetate.
Tsuchida T; Sakane T; Ishikura H; Tsunematsu T
Int J Hematol; 1991 Dec; 54(6):505-13. PubMed ID: 1793834
[TBL] [Abstract][Full Text] [Related]
55. Regulation of T cell activation by cytochrome P450 inhibitors.
Aussel C; Breittmayer JP; Ticchioni M; Pelassy C; Bernard A
Cell Immunol; 1994 May; 155(2):436-45. PubMed ID: 8181075
[TBL] [Abstract][Full Text] [Related]
56. The induction of human T cell unresponsiveness by soluble anti-CD3 mAb requires T cell activation.
Willems F; Andris F; Xu D; Abramowicz D; Wissing M; Goldman M; Leo O
Int Immunol; 1995 Oct; 7(10):1593-8. PubMed ID: 8562504
[TBL] [Abstract][Full Text] [Related]
57. Anti-CD3-activated T cells from chronic nonviremic HBV carriers are hyperreactive to monocytic accessory signals.
Baroja ML; Sirit FL; Caldera DJ; Toro FI; Zabaleta ME; Colmenares CJ; Bianco NE; Machado IV
Clin Immunol Immunopathol; 1993 Nov; 69(2):180-8. PubMed ID: 8403555
[TBL] [Abstract][Full Text] [Related]
58. Impaired interleukin-2 production in T-cells from a patient with Wiskott-Aldrich syndrome: basis of clinical effect of interleukin-2 replacement therapy.
Azuma H; Oshima M; Ito K; Okuno A; Kawabata I; Banba K; Murahashi H; Sekine T; Kato Y; Ikebuchi K; Ikeda H
Eur J Pediatr; 2000 Aug; 159(8):633-4. PubMed ID: 10968249
[TBL] [Abstract][Full Text] [Related]
59. Sialophorin, a surface sialoglycoprotein defective in the Wiskott-Aldrich syndrome, is involved in human T lymphocyte proliferation.
Mentzer SJ; Remold-O'Donnell E; Crimmins MA; Bierer BE; Rosen FS; Burakoff SJ
J Exp Med; 1987 May; 165(5):1383-92. PubMed ID: 3572301
[TBL] [Abstract][Full Text] [Related]
60. Evidence for antigenic selection of large granular lymphocytes in a patient with Wiskott-Aldrich syndrome.
Sottini A; Bettinardi A; Quiròs-Roldan E; Plebani A; Airò P; Primi D; Imberti L
Blood; 1995 Sep; 86(6):2240-7. PubMed ID: 7545024
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
